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Abstract
Introduction. Hepatitis A (HA) is caused by infection with the hepatitis A virus (HAV). The differential etiological diagnosis of 
acute hepatitis is based on a positive result of the serological test detecting IgM class anti-HAV. For epidemiological studies 
on past infection and seroprevalence of HAV in populations, the tests measuring IgG class anti-HAV or total anti-HAV are 
used. Since the 1990s, specific prophylaxis is possible by vaccination against HA. In Poland, vaccination is recommended 
and in majority is performed at own cost.  
Materials and method. Database was obtained from electronic medical records of the 2 major private health care providers 
networks (Luxmed and Medicover) operating in Poland. During a 3-year period (2013–2015), 1,124 persons with unknown 
status of anti-HA vaccination were tested for the presence of total anti-HAV.  
Objective. The aim of the study was to evaluate the seroprevalence of anti-HAV among working professionals in Poland.  
Results. Anti-HAV were detected in 603 (53.6%) persons, while 521 (46.3%) tested negative. The study group was divided 
into 2 subgroups: 25–44 and 45–64-years-old. For detailed statistical analysis, the presence of anti-HAV was considered as 
a dependent variable, and its predictors were gender, age and the year of the test performance. The presence of anti-HAV 
was significantly more prevalent in older age group. The lack of specific antibodies was more prevalent in younger age 
group.  
Conclusions. Results of the study show increasing susceptibility to HAV infection in the younger age group, compared with 
the older age group of corporate professional employees in large cities in Poland. Since the epidemiological situation of HA 
is currently changing with increasing number of symptomatic cases of HA, it is suggested that employers might consider 
including an additional procedure of vaccination against HA into their private health insurance portfolio.
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INTRODUCTION
Hepatitis A (HA) is caused by infection with the hepatitis 
A virus (HAV). The virus belongs to family Picornaviridae 
and genus Hepatovirus, is non-enveloped, has an icosahedral 
appearance with a diameter of 27 nm, and inside the virion 
there is a single-stranded RNA. Seven HAV genotypes 
were described and of these, 4 may infect humans [1]. The 
virus was visualized for the first time in stool specimens by 
immune electron microscopy in 1973 by Feinstone et al. [2]. 
The occurrence of HAV infection is routinely diagnosed 
serologically by detection of specific anti-HAV in a serum 
sample. In a study on the class-specific immune response in 
symptomatic patients admitted to a hospital with acute HA, 
in all of them had IgA and IgM anti-HAV detected, while 
IgG anti-HAV was detectable in 37% of them. IgG anti-HAV 
became detectable in all the patients beginning from the third 
week after admittance [3]. At present, for routine differential 
diagnosis of acute hepatitis cases, the presence of IgM-anti-
HAV proves etiology of HA, while for epidemiological studies 
on past infection, mainly the tests measuring IgG anti-HAV 
or total anti-HAV are used.
HA occurs worldwide in the form of sporadic cases or 
epidemic outbreaks. HAV is transmitted by the faecal-
oral route, by person-to-person contact, or ingestion of 
contaminated food or water. A number of studies on the 
possibility of infection with HAV among blood or blood 
products recipients, or haemodialysed patients, have not 
confirmed that such procedures may be relevant in HAV 
transmission. Blood transfusion from donors who were 
symptomless for hepatitis, but where the transmission 
of HAV occurred were just casuistic [4, 5]. Nevertheless, 
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a study from Latvia showed that a community outbreak 
comprising 2,800 cases of HA after blood transfusion did 
occur [6]. Transplacental transmission of HAV has not been 
reported [7].
Currently, infection with HAV – both symptomatic and 
asymptomatic – is predominant in developing countries 
with poor sanitary and hygienic conditions. Risk groups for 
acquiring HAV infection among people living in developed 
countries are health care workers taking care of both children 
and adults, people living in overcrowded situations, and 
close personal contacts, e.g. soldiers or prisoners, workers 
maintaining sewage systems, and travelers to tropical 
countries. For a number of years, due to multiple outbreaks 
of HA among men who have sex with men (MSM), that 
group is also considered at risk of HAV infection [8]. An 
important source of epidemic outbreaks could also be 
associated with frozen food which, due to the global trade 
of potentially contaminated products, may be responsible for 
multi-country outbreaks of HAV infection [9]. However, the 
possibility of prophylaxis against HA has become possible 
since the 1990s when specific vaccines were marketed [10]. 
At present, vaccination against HA is performed in some 
countries on a mass scale, in other countries the vaccine is 
offered on demand to individual persons or to people exposed 
to HAV due to their work.
OBJECTIVE
The aim of the study was to evaluate the seroprevalence 
of anti-HAV among working professionals in Poland. The 
professionals were predominantly living in large Polish cities 
and working in corporate companies which provided them 
with private health insurance and access to private health 
care providers.
MATERIALS AND METHOD
Database was obtained from electronic medical records of 2 
major private health care providers networks (LUXMED and 
MEDICOVER) operating in Poland. Both providers operate 
in 11 of 16 capitals of administrative regions (Voivodships). 
All the employees had private health insurance covered by 
their employer, in addition to health insurance guaranteed 
by the State. Inclusion criteria were as follows: a person had 
access to a general practitioner; her/his status of vaccination 
against HAV was unknown; have had the serological test 
detecting total anti-HAV performed, as referred by the 
physician within the study period. Data entailed anonymized 
information on a unique patient identifier, age, gender, year 
when the test was performed (year of test), and test results 
(positive or negative).
During a 3-year period (2013–2015), 1,124 persons 
were tested for the presence of total anti-HAV. Testing 
was performed in VIDAS automatic immunoanalyzer 
(BioMerieux).
RESULTS
The study group consisted of persons between the ages of 25 – 
64 (mean=38.79; SD=9.71), 536 of them were women (47.7%) 
and 588 (52.3%) were men. Both gender groups had similar 
age distribution. The majority of tests were performed in 2013 
(n=514; 45.7%) and 2014 (n=411; 36.6%), while in 2015, 199 
tests (17.7%) were registered. Anti-HAV were detected in 603 
(53.6%) persons, while 521 (46.3%) persons tested negative.
Presence of anti-HAV was considered as a dependent 
variable, and its predictors were gender, age and year of the 
test performance. Logistic regression analysis was applied 
in order to evaluate the main effects of those predictors and 
interactions among them. Firstly, the model that comprised 
all predictors and all possible interactions was analysed. 
In further models, the number of interactions was limited, 
starting from the most and moving to less saturated. Table 1 
presents the regression coefficients obtained for the first 
model with all predictors and interaction effects.
Table 1. Regression coefficient – saturated model
Predictors B Wald df p
Gender -17.27 0.01 1 0.960
Age 0.05 26.78** 1 0.001
Year of test -0.06 0.24 1 0.627
Gender * Year of test 0.01 0.00 1 0.963
Year of test * Age 0.01 87.06** 1 0.001
Gender * Age 0.03 4.42* 1 0.035
Gender * Year of test * Age 0.01 4.44* 1 0.035
* – p<0,05; ** – p<0.01
Outcomes were statistically significant and showed a 
relationship between the anti-HAV results and age of the 
tested persons (OR=1.05). Presence of anti-HAV was more 
prevalent in the group of older participants. There were 
also significant interactions between: year of test and age, 
gender and age. Also, the second-order interaction among 
gender and year of test and age was statistically significant. 
Interaction means that the relationship between 2 variables is 
modified by another variable or variables. The second-order 
interaction in this instance can be interpreted in terms of the 
effect that the age of participants influenced the relationship 
between the anti-HAV results and gender, and in terms 
of possible differences in this effect, between the results 
acquired in 2013 and in the 2014–2015 period.
In order to analyse differences between the younger and 
older working professionals, the study group was divided into 
2 subgroups: 25–44 and 45–64-years-old. Table 2 summarizes 
the distribution of anti-HAV results in those groups.
Table 2. Distribution of anti-HAV seroprevalence in younger and older 
working professionals
Test results
Age group
Anti-HAV 
positive
Anti-HAV 
negative
Total
n % n % n %
25–44 407 47.8 445 52.2 852 100
45–64 196 72.1 76 27.9 272 100
Total 603 53.6 521 46.4 1,124 100
Pearson’s chi-squared test c2 proved the relationship 
between age group and anti-HAV seroprevalence to be 
statistically significant (c2(1)=48.91; p<0.001). In the 
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older group of participants aged 45–64, the anti-HAV 
seroprevalence was substantially higher.
In order to interpret the second-order interaction, the study 
groups were finally divided into 2 subgroups, according to the 
year of test – 2013 and 2014–2015. Table 3 presents regression 
coefficients obtained in the regression models concerned with 
relationship between gender and HAV seroprevalence in the 
2 age groups, depending on the year of study.
Table 3. Results obtained in the regression models concerned with 
relationship between gender and HAV seroprevalence in the 2 age 
groups, depending on the year of study
Group B OR Wald df P
Age group 25–44 (2013) -0.46 0.63 5.13* 1 0.023
Age group 45–64 (2013) 0.21 1.26 2.37 1 0.123
Age group 25–44 (2014–2015) -0.25 0.78 1.80 1 0.179
Age group 45–64 (2014–2015) -0.06 0.94 0.03 1 0.867
B – unstandardized regression coefficients; OR – odds ratio; Wald – Wald test; df – degrees of 
freedom; p – statistical significance; * p<0.05
In the 25–44 age group in the study conducted in 2013, 
there was a statistically significant relationship between 
gender and HAV seroprevalence. Presence of anti-HAV was 
more prevalent in the group of women aged 25–44 years 
tested in 2013, than in the group of men aged 25–44 tested 
in the same year. According to Cox and Snell, the R2 measure 
percent of variance accounted for 1.3%. This means that 1.3% 
differences between participants in terms of being anti-HAV 
positive or anti HAV negative can be ascribed to gender.
There were no statistically significant relationships in the 
other 3 subgroups.
DISCUSSION
HA is usually a self-limiting disease in a large part of cases 
with asymptomatic course; however, both symptoms and 
severity of illness might be age-related. In children, it is mostly 
asymptomatic, but adults are more likely to present clinical 
symptoms. HAV infection in adults results in significant 
morbidity, hospitalizations, and sometimes mortality 
if HA ends in fulminant hepatitis. The normalization of 
biochemical liver function test may take several weeks or 
months [10].
A major breakthrough in the prophylaxis of HA was the 
marketing of efficient vaccines [11]. The WHO states that in 
a relatively large proportion of the adult population living 
in countries with diminishing HA endemicity, susceptibility 
to HAV is growing, and large-scale vaccination is likely to 
be cost-effective [10].
For employers, HA in the adult working population is 
connected with absenteeism [12, 13]. Immunity against 
HAV infection among working professional aged 25–64 
may be of concern for employers. Lack of immunity, which 
means susceptibility to HAV infection, was found in 46.3% of 
persons in a cohort of adults aged 25–64, investigated by the 
authors of the current study. Although their vaccination status 
against HA was unknown, in general, the seroprotection rate 
in the studied group showed that it increases with age. More 
than 72% of persons aged 45 and above were immune to 
HAV, while in groups of persons aged 25–44, susceptibility 
to HAV infection was lower in the younger age groups. 
Such a pattern is typical for countries which have changed 
from intermediate to low HAV endemicity [10]. A study 
from the USA indicates an increasing trend towards the 
hospitalization of new HA cases, together with an increase 
in the mean age of fatal outcomes [14].
There are 2 main sources of information on HAV infection 
in a geographical setting: serological surveys indicating 
past infection and epidemiological surveillance on clinical 
cases of HA. The first serological survey on anti-HAV in 
Poland showed that in the population aged over 18, more 
than 90% were seropositive in a studied country region [15]. 
The serological surveys during the following years showed a 
continuous decrease in seropositive subjects [16, 17]. This was 
accompanied by shrinking numbers of reported HA cases. At 
present, it is mandatory to notify all HA cases in Poland, and 
the National Institute of Public Health (NIPH) in Warsaw 
is responsible for epidemiological surveillance. At the time 
period of the current study, a countrywide surveillance on 
symptomatic HA cases indicated a very low endemicity, 
similar to other developed countries [10]. During the years 
of this study (2013, 2014 and 2015), the number of HA cases 
noted in Poland was 48, 76 and 49, respectively. The incidence 
per 100,000 inhabitants was 0.12, 0.20 and 0.13, respectively 
[18, 19, 20].
Such an epidemiological situation as that of 2013–2015 
continued in 2016, with 35 noted cases of HA, and the 
incidence of 0.09/100 000 inhabitants. However, in 2017, an 
unexpected increase in the number of symptomatic HA cases 
took place, with 3,072 cases and incidence of 7.99/100 000 
inhabitants [21]. A similar situation has also been noted in 
other European countries, mainly affecting groups of MSM 
[22]. The reasons for the quite rapid increase in the numbers 
of HA cases in Poland have not yet been fully explained, and 
epidemiological data are now being analysed at the NIPH. 
Taking into account the negative scenario, it seems that the 
modelling of the future incidence of HA in Poland might 
resemble that of the USA [14].
Currently, vaccination against HA in Poland is not 
obligatory, but recommended at own cost or at the cost of 
an employer, to 3 groups of people: travelers to endemic 
regions, people working at the production and distribution 
of food, or those dealing with communal wastage systems. 
It is also recommended to pre-school or school children or 
teenagers who had not been vaccinated previously.
Based on the presented data and on the changing 
epidemiological situation of HAV infection in Poland, it is 
suggested that employers might include into their private 
health insurance portfolio an additional procedure of 
vaccination against HA. At least the most susceptible younger 
age groups of employees should be included. According to 
the WHO, just one dose of the vaccine might be sufficient to 
provide immunity against HAV infection [10].
CONCLUSIONS
Results of the study show increasing susceptibility to HAV 
infection in the younger age group of corporate professional 
employees in large cities in Poland. Nowadays, in order to 
prevent HA, specific prophylaxis with vaccines is possible. 
In Poland, vaccination against HA is recommended and 
performed at own cost. Since the epidemiological situation 
of HA is currently changing, it is suggested that employers 
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might consider the inclusion of an additional procedure of 
vaccination against HA into their private health insurance 
portfolio.
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